JHVEPhoto Johnson & Johnson ( NYSE: JNJ ) said it has submitted an application for FDA approval of its drug Tremfya for the treatment of moderately to severely active Crohn’s disease. The announcement comes hours after the pharmaceutical giant reported positive Phase 3 data for the drug as a subcutaneous therapy for the condition. The company submitted an application in March for approval of Tremfya in the treatment of moderately to severely active ulcerative colitis, according to a statement .
Tremfya, an IL-23 inhibitor, is currently approved by the FDA for the treatment of moderate-to-severe plaque psoriasis and active psoriatic arthritis. More on Johnson & Johnson Johnson & Johnson (JNJ) Goldman Sachs 45th Annual Global Healthcare Conference (Transcript) Johnson & Johnson: Market Will Regret The Overreaction Johnson & Johnson (JNJ) Bernstein's 40th Annual Strategic Decisions Conference - (Transcript) J&J Phase 3 study shows subcutaneous Tremfya effective in Crohn's J&J's Talvey demonstrates robust long-term response in multiple myeloma.
